Copyright © 2015 - 2022 Lifecarenews.in
LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283
Hepion Pharmaceuticals Schedules Conference Call to Review
EDISON, N.J., May 19, 2023 (GLOBE NEWSWIRE) -- Hepion…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Hepion
Hepion Pharmaceuticals to Present Data on Synergistic
EDISON, N.J., April 17, 2023 (GLOBE NEWSWIRE) -- Hepion…
Hepion Pharmaceuticals to Deliver Updates on Ongoing Phase
<!-- Name:DistributionId Value:8780828 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4577 -->…
Hepion Pharmaceuticals to Ring the NASDAQ Stock Market
<!-- Name:DistributionId Value:8746513 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->
<!-- Name:IcbCode Value:4577 -->…
- Advertisement -
Hepion Pharmaceuticals to Present Phase 2a Rencofilstat
EDISON, N.J., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of…
Hepion Pharmaceuticals, Inc. Granted 180-day Extension by
EDISON, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (Nasdaq:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of…
Hepion Pharmaceuticals Announces Pricing of $20.0 Million
EDISON, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of…